Structure · schematic
Peptide chain · Sonstiges
Schematic representation of the amino acid chain — not a chemical structural formula. Each node represents one amino acid.
Research areas*
* Contexts in which the peptide has been scientifically studied — not assured or recommended effects.
Mechanism of action
- ACE-031 is a soluble decoy receptor: a fusion protein of the extracellular domain of activin receptor type IIB (ActRIIB) and an antibody Fc portion.
- It binds myostatin and related ligands before they can dock onto their cellular receptor, thereby removing their growth-inhibiting effect on muscle.
- An increase in muscle mass has consequently been described in studies.
- ACE-031 is not a classic peptide but a recombinant fusion protein.
Research status
- ACE-031 was investigated in early clinical studies.
- A single-ascending-dose study in healthy postmenopausal women documented an increase in muscle-mass markers.
- A study in boys with Duchenne muscular dystrophy was stopped early for safety reasons (including nosebleeds, gum bleeding, telangiectasia).
- Development was discontinued; there is no approval.
Evidence level
Cited studies
Known risks
- 01Trial stopped due to bleeding tendency and telangiectasia
- 02Nosebleeds and gum bleeding described
- 03Interference with myostatin signalling with unclear long-term consequences
- 04WADA ban (S4)
- 05Product quality cannot be verified from unapproved sources
Frequently asked questions
What is ACE-031?
ACE-031 is a soluble decoy receptor: a fusion protein of the extracellular domain of activin receptor type IIB (ActRIIB) and an antibody Fc portion.
What type of peptide is ACE-031?
ACE-031 belongs to the Other class.
Is ACE-031 legal in Germany?
ACE-031 is not approved as a medicine in Germany. Obtaining it outside clinical studies is legally problematic.
Where can I buy ACE-031?
Peptica sells nothing and names no sources. ACE-031 is "not approved" in Germany; obtaining unapproved substances outside clinical studies is illegal and carries quality and safety risks.
Is ACE-031 banned in sport (WADA)?
Yes. ACE-031 is on the WADA Prohibited List and is therefore banned in competitive sport.
What are the known risks of ACE-031?
Documented risks include: Trial stopped due to bleeding tendency and telangiectasia; Nosebleeds and gum bleeding described. This is not a complete safety assessment and not medical advice — see the risks section for the full list.
How well researched is ACE-031?
The evidence is classified as “early clinical studies”. 2 studies are cited on this page.
Legal status
Germany
not approvedAustria
not approvedSwitzerland
not approvedEU
not approvedUSA
not approvedCanada
not approvedLegal status varies by country and can change. This is not legal advice.
Sources & methodology
- 2 peer-reviewed studies cited, linked to PubMed where available.
- Molecular data verified against PubChem and primary literature.
- Editorial standard: no dosage guidance, no sources, evidence level stated explicitly.
Last editorially reviewed: 30 May 2026
Legal assessment
ACE-031 is not approved as a medicine; clinical development was discontinued. As a myostatin-inhibiting agent it falls under the WADA Prohibited List (S4, myostatin inhibitors). Obtaining it as a research chemical is illegal and carries considerable safety risks.
Important notice
This site is intended solely for factual, scientifically oriented information about peptides. It does not constitute medical advice, does not replace a consultation with a doctor and contains no recommendations for use in humans.
This site does not sell any substances and names no sources for unapproved substances. For medical questions, please consult qualified medical professionals.
Anzeige
Reserviert für sorgfältig ausgewählte Partner — Telemedizin, Diagnostik, legale topische Anwendungen.